Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Zúñiga-Ramírez C, Otero-Cerdeira E, Camacho-Ordóñez A, González-Latapi P, Morales-Briceño H, Martínez-Ramírez D

Language: Spanish
References: 14
Page: 76-80
PDF size: 616.74 Kb.

ABSTRACT

Introduction: Pramipexole is a dopamine agonist effective to treat the motor symptoms of Parkinson disease available as immediate or extended release. Objective: The aim of this study is to determine whether there are differences in the profile of patients receiving pramipexole according to the formulation used. Methods: A crosssectional retrospective study was conducted which reviewed the information of 464 patients belonging to the Mexican Parkinson’s Disease registry (ReMePARK) treated with stable doses of pramipexole. Data were collected including demographic and clinical information along with severity and motor scales. Dose and formulation of patients receiving pramipexole was collected. A regression model was used to identify associated factores. Results: About 69.4% of patients were on the immediate release formulation, only 31.7% were on monotherapy. The mean dose of pramipexole immediate release was 1.7 ± 1.2 mg, while the extended release dose was 1.9 ± 1.1 mg (p = 0.09). Patients receiving pramipexole extended release were younger (p = 0.048), with more years of formal education (p ‹ 0.001) and were receiving it as monotherapy (p ‹ 0.001). Conculsion: No differences in the doses of pramipexole immediate and extended release was found. Patients receiving pramipexole extended release were younger, in monotherapy and had more years of formal education.

REFERENCES

1. Miyasaki JM. Evidence-based initiation of dopaminergic therapy in Parkinson’s disease. J Neurol 2010; 257(Suppl. 2): S309-13.

2. Jenner P, Konen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009; 31: 2698-711.

3. Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011; 77: 759-66.

4. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson’s disease: a randomized controlled trial. Neurology 2011; 77: 767-74.

5. Chwieduk CM, Curran MP. Pramipexole extended release: in Parkinson’s disease. CNS Drugs 2010; 24: 327-36.

6. Sesar A, Arbelo JM, del Val JL. Treatment of Parkinson disease, time and dosage: does simple dosage facilitate compliance and therapeutic goals? Neurologist 2011; 17: S43-6.

7. Salawu FK. Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole. Patient Prefer Adherence 2012; 6: 49-54.

8. Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Otero-Cerdeira E, Dávila-Ortiz D, et al. Estudio para una cohorte multicéntrica de pacientes mexicanos con enfermedad de Parkinson para evaluar los determinantes motores, no motores y genéticos sobre la progresión. Arch Neurocien (Mex) 2012; 17: 159-64.

9. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.

10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.

11. Martínez-Martín P, Rodríguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s disease rating scale (MDS-UPDRS). J Neurol 2013; 260: 228-36.

12. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol 2013; 20: 50-6.

13. Dujardin K, Leentjens AF, Langlois C, Moonen AJ, Duits AA, Carette AS, et al. The spectrum of cognitive disorders in Parkinson’s disease: A data-driven approach. Mov Disord 2013; 28: 183-9.

14. Steenland K, MacNeil J, Seals R, Levey A. Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology 2010; 35: 28-35.